Physician profile
Howard B Epstein
NPI 1295786242
$3,724.59
in general payments reported to CMS, 2019-2025
23 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $257 · 2021: $1,634 · 2022: $421 · 2023: $69.77 · 2024: $152 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,837.41 | 2020-2024 | Axonics |
| Astellas Pharma US INC | $593.56 | 2019-2025 | Xtandi, Myrbetriq |
| Cook Medical LLC | $152.02 | 2019-2021 | |
| Myovant Sciences INC. | $139.81 | 2021-2022 | |
| Pfizer INC. | $132.01 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $124.65 | 2019 | |
| Janssen Biotech, INC. | $112.63 | 2019 | |
| Allergan, INC. | $83.01 | 2019 | |
| Merck Sharp & Dohme LLC | $82.07 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Amgen INC. | $74.88 | 2019 | |
| Blue Earth Diagnostics | $73.21 | 2019-2025 | Posluma |
| Olympus America INC. | $49.21 | 2019-2023 | Itind System |
| Urogen Pharma, INC. | $46.31 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $41.52 | 2020 | |
| Medtronic, INC. | $33.38 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.60 | 2022 | |
| Boston Scientific Corporation | $29.03 | 2019-2025 | Axonics |
| Teleflex LLC | $28.23 | 2025 | Urolift |
| Medtronic USA, INC. | $24.92 | 2019 | |
| Coloplast Corp | $21.43 | 2019 | |
| Tolmar, INC. | $15.70 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.